Incidence, etiology, and risk factors for liver dysfunction in children following hematopoietic stem cell transplantation

Pediatric Transplantation

Volumn 10, Issue 6, 2006, Pages 682-689

  Subbarao, Girish ^a   Haut, Paul R ^a   Johnson, Cynthia S ^a   Gowan, Darla ^a   Molleston, Jean P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Children; Hematopoietic stem cell transplantation; Liver dysfunction; Risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; BILIRUBIN; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; GAMMA GLUTAMYLTRANSFERASE; MELPHALAN; METHOTREXATE; PREDNISONE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW DEPRESSION; CAUSE OF DEATH; CELL ACTIVITY; CHILD; CLINICAL ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; JAUNDICE; LEUKEMIA; LIVER DYSFUNCTION; LIVER GRAFT REJECTION; LIVER TOXICITY; LYMPHOMA; MALE; MORTALITY; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; SOLID TUMOR; TOTAL PARENTERAL NUTRITION; UNIVARIATE ANALYSIS; VEIN OCCLUSION; VIRUS HEPATITIS;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFANT; JAUNDICE; LIVER DISEASES; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 33746927511     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00532.x     Document Type: Article

References (40)

1. ARMITAGE JO. Bone marrow transplantation. N Engl J Med 1994: 330: 827-838.
2. KIM BK, CHUNG KW, SUN HS, et al. Liver disease during the first post-transplant year in bone marrow transplantation recipients: Retrospective study. Bone Marrow Transplant 2000: 26: 193-197.
3. EL-SAYED MH, EL-HADDAD A, FAHMY OA, SALAMA II, MAHMOUD HK. Liver disease is a major cause of mortality following allogeneic bone-marrow transplantation. Eur J Gastroenterol Hepatol 2004: 16: 1347-1354.
4. SOIFFER RJ, DEAR K, RABINOWE SN, et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation 1991: 52: 1014-1019.
5. OZDOGAN O, RATIP S, AHDAB YA, et al. Causes and risk factors for liver injury following bone marrow transplantation. J Clin Gastroenterol 2003: 36: 421-426.
6. FARTHING MJG, CLARK ML, SLOANE JP, POWLES RL, MCELWAIN TJ. Liver disease after bone marrow transplantation. Gut 1982: 23: 465-474.
7. LOCASCIULLI A, TESTA M, VALSECCHI MG, et al. The role of hepatitis C and B virus infections as risk factor for severe liver complications following allogeneic BMT: A prospective study by the infectious disease working party of the European blood and marrow transplantation group. Transplantation 1999: 68: 1486-1491
8. FRISK P, LONNERHOLM G, OBERG G. Disease of the liver following bone marrow transplantation in children: Incidence, clinical course and outcome in a long-term perspective. Acta Paediatr 1998: 87: 579-583.
9. LOCASCIULLI A, TESTA M, VALSECCHI MG, et al. Morbidity and mortality due to liver disease in children undergoing allogeneic bone marrow transplantation: A 10-yr prospective study. Blood 1997: 90: 3799-3805.
10. National Cancer Institute. Common Toxicity Criteria (Database Online) Version 2. Bethesda, MD: National Cancer Institute, 1999. http://ctep.cancer. gov/reporting/CTC-3test. html (Updated April 30, 1999).
11. FORBES GM, DAVIES JM, HERRMANN RP, COLLINS BJ. Liver disease complicating bone marrow transplantation: A clinical audit. J Gastroenterol Hepatol 1995: 10: 1-7.
12. ABRAHAM E, MATTHAY MA, DINARELLO CA, et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation. Crit Care Med 2000: 28: 232-235.
13. JONES RJ, LEE KS, BESCHORNER WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987: 44: 778-783.
14. MCDONALD GB, HINDS MS, FISHER LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993: 118: 255-267.
15. HORN B, REISS U, MATTHAY K, MCMILLAN A, COWAN M. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: A high incidence in patients with neuroblastoma. Bone Marrow Transplant 2002: 29: 409-415.
16. WOODS WG, NEUDORF S, GOLD S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: A report from the Children's Cancer Group. Blood 2001: 97: 56-62.
17. MATSUYAMA T, HORIBE K, KATO K, KOJIMA S. Bone marrow transplantation for children with acute myelogenous leukemia in the first complete remission. Eur J Cancer 2000: 36: 368-375.
18. LEVINE JE, HARRIS RE, LOBERIZA FR JR, et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003: 101: 2476-2482.
19. WEISDORF D, BISHOP M, DHARAN B, et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant 2002: 8: 213-220.
20. BARKER CC, BUTZNER JD, ANDERSON RA, BRANT R, SAUVE RS. Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2003: 32: 79-87.
21. RICHARDSON P, BEARMAN SI. Prevention and treatment of hepatic venoocclusive disease after high-dose cytoreductive therapy. Leuk Lymphoma 1998: 31: 267-277.
22. HASEGAWA S, HORIBE K, KAWABE T, et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: Incidence, onset time and risk factors. Bone Marrow Transplant 1998: 22: 1191-1197.
23. LAWRENCE TS, ROBERTSON JM, ANSCHER MS, JIRTLE RL, ENSMINGER WD, FAJARDO LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995: 31: 1237-1248.
24. OZKAYNAK MF, WEINBERG K, KOHN D, SENDER L, PARKMAN R, LENARSKY C. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome. Bone Marrow Transplant 1991: 7: 467-474.
25. MERESSE V, HARTMANN O, VASSAL G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulphan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992: 10: 135-141.
26. AZAR N, VALLA D, ABDEL-SAMAD I, et al. Liver dysfunction in allogeneic bone marrow transplantation recipients. Transplantation 1996: 62: 56-61.
27. LOCASCIULLI A, BACIGALUPO A, ALBERTI A, et al. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation 1989: 48: 68-72.
28. STYLER MJ, CRILLEY P, BIGGS J, et al. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: A retrospective, multicenter analysis. Bone Marrow Transplant 1996: 18: 171-176.
29. ESSELL JH, THOMPSON JM, HARMAN GS, et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/ cyclophosphamide. Blood 1992: 79: 2784-2788.
30. KELLY DA. Liver complications of pediatric parenteral nutrition-epidemiology. Nutrition 1998: 14: 153-157.
31. ZAMBRANO E, EL-HENNAWY M, EHRENKRANZ RA, ZELTERMAN D, REYES-MUGICA M. Total parenteral nutrition induced liver pathology: An autopsy series of 24 newborn cases. Pediatr Dev Pathol 2004: 7: 425-432.
32. DIACONESCU R, FLOWERS CR, STORER B, et al. morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004: 104: 1550-1558
33. HOGAN WJ, MARIS M, STORER B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: A study of 193 patients. Blood 2004: 103: 78-84.
34. KLINGEMANN HG, SHEPHERD JD, REECE DE, et al. Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies. Bone Marrow Transplant 1994: 14: S14-S18.
35. RUUTU T, ERIKSSON B, REMES K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002: 100: 1977-1983.
36. BROWN SA, GORINGE A, FEGAN C, et al. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant 1998: 22: 281-284.
37. YANNAKI E, ATHANASIOU E, XAGORARI A, et al. G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs. Exp Hematol 2005: 33: 108-119.
38. BUCHMAN A. Total parenteral nutrition-associated liver disease. J Parenter Enteral Nutr 2002: 26: S43-S48.
39. STRASSER SI, SULLIVAN KM, MYERSON D, et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999: 93: 3259-3266.
40. TOMAS JF, PINILLA I, GARCIA-BUEY ML, et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: Clinical features and course in 61 patients. Bone Marrow Transplant 2000: 26: 649-655.